Your browser doesn't support javascript.
loading
Inflammatory cerebrospinal fluid markers in schizophrenia spectrum disorders: A systematic review and meta-analysis of 69 studies with 5710 participants.
Warren, Nicola; O'Gorman, Cullen; Horgan, Isabelle; Weeratunga, Milleni; Halstead, Sean; Moussiopoulou, Joanna; Campana, Mattia; Yakimov, Vladislav; Wagner, Elias; Siskind, Dan.
Afiliação
  • Warren N; The University of Queensland, Faculty of Medicine, Brisbane, Australia; Metro South Addiction and Mental Health Service, Metro South Health, Brisbane, Australia. Electronic address: n.warren@uq.edu.au.
  • O'Gorman C; The University of Queensland, Faculty of Medicine, Brisbane, Australia; Department of Neurology, Metro South Health, Brisbane, Australia.
  • Horgan I; Gold Coast University Hospital, Gold Coast, Australia.
  • Weeratunga M; The University of Queensland, Faculty of Medicine, Brisbane, Australia.
  • Halstead S; The University of Queensland, Faculty of Medicine, Brisbane, Australia.
  • Moussiopoulou J; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
  • Campana M; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
  • Yakimov V; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany; International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany.
  • Wagner E; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
  • Siskind D; The University of Queensland, Faculty of Medicine, Brisbane, Australia; Metro South Addiction and Mental Health Service, Metro South Health, Brisbane, Australia.
Schizophr Res ; 266: 24-31, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38364730
ABSTRACT

BACKGROUND:

There is increasing evidence of immune dysregulation and neuroinflammation occurring in schizophrenia. The aim of this study is to combine studies on routine CSF parameters, as well as cytokines and inflammatory proteins, in individuals with schizophrenia spectrum disorders.

METHODS:

CSF parameters were summated and inverse variance meta-analyses using a random effects model were performed comparing mean difference or odds ratios. Between study heterogeneity was assessed using the I2 statistic. Quality assessment and sensitivity analyses were performed.

RESULTS:

There were 69 studies of 5710 participants, including 3180 individuals with schizophrenia spectrum disorders. Averaged CSF parameters were within normal limits, however, between 3.1 % and 23.5 % of individual cases with schizophrenia spectrum disorders had an abnormal CSF

result:

Protein (abnormal in 23.5 % cases), albumin (in 18.5 %), presence of oligoclonal bands (in 9.3 %), white blood cell count (in 3.6 %), and IgG levels (3.1 %). Meta-analysis of 55 studies with non-psychiatric controls demonstrated a significant increase in CSF total protein (MD 3.50, CI 0.12-6.87), albumin ratio (MD 0.55, CI 0.02-0.09), white cell count (MD 0.25, CI 0.05-0.46), IL-6 (SMD 0.53, CI 0.29 to 0.77) and IL-8 (SMD 0.56, CI 0.11 to 1.01). Sensitivity analysis did not alter findings.

CONCLUSION:

Abnormal CSF parameters, cytokines and inflammatory proteins were found in a significant proportion of individuals with schizophrenia spectrum disorders. This may indicate alterations to blood brain barrier function and permeability, CSF flow dynamics or neuroinflammation. Further research is needed to explore these potential mechanisms.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Esquizofrenia Limite: Humans Idioma: En Revista: Schizophr Res Assunto da revista: PSIQUIATRIA Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Esquizofrenia Limite: Humans Idioma: En Revista: Schizophr Res Assunto da revista: PSIQUIATRIA Ano de publicação: 2024 Tipo de documento: Article